NCT02943863

Brief Summary

High-flow nasal cannula (HFNC) that uses heated and humidified oxygen was recently introduced for bedside care. It has been shown to be associated with reduced risks of tracheal intubation rates and mortality in adult hypoxic patients. The mechanisms of the effects of HFNC are thought to be related to the favorable effects of the heated and humidified gas, the high-flow rate used to minimize the entrainment of room air, and an increase in the ventilation efficiency, including the elimination of nasopharyngeal dead space, positive end-expiratory pressure (PEEP) effects, and improvements in paradoxical abdominal movement. Regarding the effects on lung volume, global ventilation in the lungs increases during HFNC, which is thought to attribute to PEEP effects. However, how regional ventilation is affected during HFNC in comparison with conventional NC remains unknown. Because PEEP in mechanically ventilated patients improves the regional homogeneity of ventilation, investigators postulated that HFNC via PEEP effects would result in more homogeneous regional distributions in the ventilation changes. Investigators therefore assessed global and regional ventilation in patients with hypoxia receiving care via HFNC using electric impedance tomography and compared these results with conventional nasal cannula.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2014

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2015

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

October 21, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 25, 2016

Completed
Last Updated

October 25, 2016

Status Verified

October 1, 2016

Enrollment Period

5 months

First QC Date

October 21, 2016

Last Update Submit

October 23, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Tidal variation

    Tidal variation using electric impedance tomography

    Twenty minutes after each oxygen therapy. (At the end of each oxygen therapy)

Secondary Outcomes (3)

  • Oxygen saturation

    Twenty minutes after each oxygen therapy. (At the end of each oxygen therapy)

  • Respiration Rate

    Twenty minutes after each oxygen therapy. (At the end of each oxygen therapy)

  • Subjective comfort

    Twenty minutes after each oxygen therapy. (At the end of each oxygen therapy)

Study Arms (2)

HFNC first

ACTIVE COMPARATOR

Patients in "HFNC first" receive oxygen therapy using HFNC in ahead of conventional nasal cannula oxygen therapy. After 20 minutes of HFNC therapy, patients receive conventional nasal cannula oxygen therapy.

Device: HFNC followed by conventional nasal cannula

LFS first

ACTIVE COMPARATOR

Patients in "LFS first" receive oxygen therapy using conventional nasal cannula in ahead of HFNC therapy. After 20 minutes of conventional nasal cannula oxygen therapy, patients receive HFNC oxygen therapy.

Device: Conventional nasal cannula followed by HFNC

Interventions

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>20 years
  • Subjective dyspnea in room air
  • SaO2\< 90% in room air
  • Oxygen requirement for nasal cannula \< 6 L/m

You may not qualify if:

  • Unstable vital signs
  • SBP \<90 mmHg
  • DBP \< 60 mmHg
  • Heart rate \> 120 bpm
  • Respiratory rate \> 30 bpm
  • Persistent dyspnea under oxygen therapy using NC
  • Severe hypoxia
  • PaO2/FiO2\< 200 mmHg
  • Unable to cooperate
  • Delirium
  • Reduced cognitive function

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated Humidified High-Flow Nasal Oxygen in Adults: Mechanisms of Action and Clinical Implications. Chest. 2015 Jul;148(1):253-261. doi: 10.1378/chest.14-2871.

    PMID: 25742321BACKGROUND
  • Riera J, Perez P, Cortes J, Roca O, Masclans JR, Rello J. Effect of high-flow nasal cannula and body position on end-expiratory lung volume: a cohort study using electrical impedance tomography. Respir Care. 2013 Apr;58(4):589-96. doi: 10.4187/respcare.02086.

    PMID: 23050520BACKGROUND
  • Hsu CF, Cheng JS, Lin WC, Ko YF, Cheng KS, Lin SH, Chen CW. Electrical impedance tomography monitoring in acute respiratory distress syndrome patients with mechanical ventilation during prolonged positive end-expiratory pressure adjustments. J Formos Med Assoc. 2016 Mar;115(3):195-202. doi: 10.1016/j.jfma.2015.03.001. Epub 2015 Apr 3.

    PMID: 25843526BACKGROUND
  • Lee DH, Kim EY, Seo GJ, Suh HJ, Huh JW, Hong SB, Koh Y, Lim CM. Global and Regional Ventilation during High Flow Nasal Cannula in Patients with Hypoxia. Acute Crit Care. 2018 Feb;33(1):7-15. doi: 10.4266/acc.2017.00507. Epub 2018 Jan 22.

MeSH Terms

Conditions

HypoxiaRespiratory Aspiration

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsRespiration DisordersRespiratory Tract DiseasesPathologic Processes

Study Officials

  • Chae-Man Lim, MD

    Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Pulmonary and Critical Care Medicine, College of Medicine, University of Ulsan. Chief Director of Intensive Care Units, Asan Medical Center

Study Record Dates

First Submitted

October 21, 2016

First Posted

October 25, 2016

Study Start

September 1, 2014

Primary Completion

February 1, 2015

Study Completion

February 1, 2015

Last Updated

October 25, 2016

Record last verified: 2016-10